Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Diabetes drug liraglutide may fight fatty liver, but trial halted early

NCT ID NCT02721888

Disease control Sponsor: Centre Hospitalier Universitaire Dijon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looked at whether liraglutide, a diabetes drug, can reduce liver fat and improve cholesterol in people with type 2 diabetes. It involved 127 patients who took liraglutide for 6 months, with liver fat measured by MRI. However, the trial was terminated early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
liraglutide
What this could lead to
If successful, this could show that liraglutide helps reduce liver fat and improve cholesterol levels in people with type 2 diabetes.
What could go wrong
The trial was terminated early, so results are incomplete. It was also a small, single-center study, so findings may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

127 people

The number who actually took part.

Started

Jul 2012

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with type 2 diabetes * Patients treated by metformin and/or sulfonylureas (or glinides) and/or acarbose and/or insulin, * HbA1C \>= 7 %, * Patients who gave their written consent. For the kinetic substudy: * Patients who have the typical features of diabetic dyslipidemia (triglycerides \>= 1.50 g/l and/or HDL\<0.50 g/l \[women\], 0.40 g/l \[men\]) Exclusion Criteria: * Treatment with thiazolidinediones or other Glucagon-like peptide-1(GLP1) agonist. * No treatment with a Dipeptidyl peptidase-4 (DPP4) inhibitor during the 3 previous months, * Renal or hepatic failure, * Contra-indication for proton-spectroscopy (pacemaker, implantable prosthesis,..), * Pregnancy. For the kinetic substudy: * Patients on hypolipidemic agents

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes

Contacts and locations

Locations

  • CHU de Dijon

    Dijon, 21079, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.